Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) just unveiled an announcement.
Shanghai Junshi Biosciences Co., Ltd. announced the convening of its 2025 interim results briefing to be held on September 8, 2025. The briefing aims to provide investors with a comprehensive understanding of the company’s operating results and financial status for the first half of 2025. The event will be conducted online via the Shanghai Stock Exchange Roadshow Center, allowing investors to interact and ask questions. This initiative reflects the company’s commitment to transparency and investor engagement, potentially impacting its market perception and stakeholder relations positively.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in China, focusing on the development, production, and commercialization of innovative drugs. The company operates primarily in the pharmaceutical industry, with a market focus on providing therapeutic solutions for oncology, autoimmune, and metabolic diseases.
Average Trading Volume: 13,622,799
Technical Sentiment Signal: Buy
Current Market Cap: HK$44.53B
Find detailed analytics on 1877 stock on TipRanks’ Stock Analysis page.